Clinical Study on the Treatment of Mixed Component Cornea for High Risk Keratoplasty

Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04490902
Collaborator
(none)
80
1
2
34.4
2.3

Study Details

Study Description

Brief Summary

Because of the immunologically privileged nature of the cornea, the graft rejection rate is less than 10% for low-risk keratoplasty. But when the cornea performed 2 or more quadrants of corneal neovascularization after ocular trauma or infection, the graft rejection rate is more than 65%, it is called high-risk keratoplasty.

This study will observe the graft survival of high-risk corneal transplantation using mixed component cornea from different donors.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Limbal transplantation combined with central penetrating keratoplasty
  • Procedure: Limbal transplantation combined with central penetrating keratoplasty
N/A

Detailed Description

Ocular trauma or infection lead to corneal limbal stem cell deficiency and central corneal opacification which could only be treated by central penetrating keratoplasty and limbal transplantation, but the rejection rate is very high. In clinical, we found that limbal transplantation combined with central penetrating keratoplasty from different donors can keep the graft transparent for a long time, this result also be found in organ transplantation, multiple donor organ transplantation could reduce rejection risk in liver and kidney transplantation. Therefore, it is speculated that there are different MHC antigens from different donors, which cause different reactions after transplantation. Because there are a large number of Langerhans cells, abundant blood vessels and lymphatic in the limbal, so the rejection occurs early and severely. Continuous and intense limbal rejection leads to the depletion of recipient T cells, lead to the immune tolerance of another donor's central corneal tissue. In this project, central penetrating keratoplasty and limbal transplantation from different donors will be carried out and the graft survival of high-risk corneal transplantation will be observed in clinical, to find a new method for high-risk corneal transplant patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Suppression of Graft Rejection Using Mixed Component Cornea in the High-risk Keratoplasty,A Randomized Controlled Trial.
Actual Study Start Date :
Aug 18, 2020
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Single graft corneal transplantation

Limbal transplantation combined with central penetrating keratoplasty from single donors.

Procedure: Limbal transplantation combined with central penetrating keratoplasty
Limbal transplantation combined with central penetrating keratoplasty with single donor cornea

Experimental: Dual graft corneal transplantation

Limbal transplantation combined with central penetrating keratoplasty from different donors.

Procedure: Limbal transplantation combined with central penetrating keratoplasty
Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea

Outcome Measures

Primary Outcome Measures

  1. The rate of corneal graft rejection at 12 months [12 months]

    The rejection index of corneal transplantation will be observed by slit lamp after surgery

Secondary Outcome Measures

  1. The changes of best corrected visual acuity [Before surgery, 1 week, 1 month, 3 months, 6 months, 12 months]

    Best corrected visual acuity in different point will be compared with preoperative

  2. The changes of corneal thickness depth [baseline (Before surgery), 1 week, 1 month, 3 months, 6 months, 12 months]

    Corneal thickness depth will be measured by anterior segmental OCT and compared with preoperative

  3. Reconstruction of corneal limbal [baseline (Before surgery), 1 week, 1 month, 3 months, 6 months, 12 months]

    Confocal microscopy will be used to define whether the structure of corneal limbal has reconstructed

  4. Endothelial Cell Density [baseline (Before surgery), 1 week, 1 month, 3 months, 6 months, 12 months]

    Endothelial Cell Density will be measured by specular microscope to evaluate the loss of endothelial cells

  5. The rate of presence of goblet cells containing conjunctival epithelium on the corneal surface by impression cytology [baseline (Before surgery), 1 week, 1 month, 3 months, 6 months, 12 months]

    Detects whether conjunctival epithelial and goblet cells have invaded the corneal surface by impression cytology, to observe the reconstruction of limbal function

Other Outcome Measures

  1. Intraocular pressure [Before surgery, 1 week, 1 month, 3 months, 6 months, 12 months]

    Intraocular pressure will be measured by non contact tonometer as safety index

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Central corneal opacity involving full layer

  • Corneal neovascularization in two or more quadrants

  • Patients must be willing and able to return for scheduled follow-up examinations for 12 months after surgery

  • Ages:18 -70 Years

Exclusion Criteria:
  • Central corneal opacity not involving the endothelial layer

  • Less than two quadrants of corneal neovascularization

  • History of Stevens-Johnson syndrome or Sjogren's syndrome

  • Severe eyelid and conjunctival scar

  • Loss of vision in contralateral eye

  • Pregnant and lactating women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Zhongshan Ophthalmic Center, Sun Yat-Sen University Guangzhou Guangdong China 510080

Sponsors and Collaborators

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zhongshan Ophthalmic Center, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT04490902
Other Study ID Numbers:
  • 2020KYPJ111
First Posted:
Jul 29, 2020
Last Update Posted:
Feb 24, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Results

No Results Posted as of Feb 24, 2022